Kingmed Diagnostics was among the investors in the $44.7m round, the proceeds of which will fund development of Creative Biosciences' cancer diagnostics kits.

China-based cancer testing kit provider Creative Biosciences raised RMB300m ($44.7m) on Friday in a series B round that included two funds affiliated with medical testing services provider Kingmed Diagnostics. The round was co-led by venture capital group IDG Capital and private equity firm CDH Investments, and also featured fellow private equity firm CD Capital. Founded…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.